Skip to Content
Merck
CN

F0778

Felbamate

NMDA glutamate receptor antagonist

Synonym(s):

2-Phenyl-1,3-propanediol dicarbamate

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C11H14N2O4
CAS Number:
25451-15-4
Molecular Weight:
238.24
NACRES:
NA.77
PubChem Substance ID:
24277968
UNSPSC Code:
12352200
EC Number:
247-001-4
MDL number:
MFCD00865296
Quality level:
200

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Felbamate,

InChI key

WKGXYQFOCVYPAC-UHFFFAOYSA-N

InChI

1S/C11H14N2O4/c12-10(14)16-6-9(7-17-11(13)15)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H2,12,14)(H2,13,15)

SMILES string

NC(=O)OCC(COC(N)=O)c1ccccc1

solubility

alcohol: soluble

Quality Level

200

Gene Information

human ... GRIN1(2902), GRIN2A(2903), GRIN2B(2904), GRIN2C(2905), GRIN2D(2906), GRIN3A(116443), GRIN3B(116444)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Biochem/physiol Actions

Anticonvulsant agent that is an allosteric antagonist at the NR2B subunit of the NMDA glutamate receptor; also has γ-aminobutyric acid (GABAA) receptor agonist properties.

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000211844
0000211844
0000244737
0000228632
0000244737

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

K D Laxer
The Western journal of medicine, 161(3), 309-314 (1994-09-01)
For the first time in 15 years, new antiepileptic medications are available for the treatment of patients with seizure disorders. These drugs have demonstrated efficacy in animal models of epilepsy and in controlled clinical trials. Felbamate was licensed in 1993
Huai-Ren Chang et al.
Biophysical journal, 93(6), 1981-1992 (2007-05-22)
Felbamate (FBM) is a potent nonsedative anticonvulsant whose clinical effect is chiefly related to gating modification (and thus use-dependent inhibition) rather than pore block of N-methyl-D-aspartate (NMDA) channels at pH 7.4. Using whole-cell recording in rat hippocampal neurons, we examined
J M Pellock
Epilepsia, 40 Suppl 5, S57-S62 (1999-10-26)
Felbamate (FBM) was the first of the new antiepileptic drugs (AEDs) approved in the United States in 1993 with broad-spectrum efficacy against partial and generalized seizures of various types, and indicated for use as adjunctive and monotherapy. The identification of
Angelique M Leone et al.
Chemical research in toxicology, 20(4), 600-608 (2007-03-27)
Felbamate is an antiepileptic drug that is associated with minimal toxicity in preclinical species such as rat and dog but has an unacceptable incidence of serious idiosyncratic reactions in man. Idiosyncratic reactions account for over half of toxicity-related drug failures
J M Pellock
Drug safety, 21(3), 225-239 (1999-09-16)
Felbamate demonstrates a unique therapeutic profile and often results in seizure control when other agents fail. Its use has been associated with risks for aplastic anaemia and hepatic failure. A number of confounding factors makes the actual incidence rate for
View All Related Papers

Related Content

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service